Related Experiment Video
Updated: Jun 16, 2026
07:17
Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
Published on: August 23, 2024
Human Immunodeficiency Virus-associated anaplastic large cell lymphoma
Kimberly Perez1, Jorge Castillo, Bruce J Dezube
1Division of Hematology/Oncology, The Warren Alpert Medical School of Brown University, The Miriam Hospital, Providence, RI 02906, USA.
Leukemia & Lymphoma
|February 10, 2010
Summary
Anaplastic large cell lymphoma (ALCL) in HIV-positive individuals is rare, aggressive, and primarily extranodal. Early chemotherapy and presentation stage are good prognostic factors, with HAART showing a survival trend.
Area of Science:
- Oncology
- Immunology
- Infectious Diseases
Background:
- Anaplastic large cell lymphoma (ALCL) is a CD30-expressing peripheral T-cell lymphoma (PTCL).
- HIV infection increases the risk of PTCL, but HIV-associated ALCL is infrequently reported.
- Limited data exists on the characteristics and outcomes of ALCL in HIV-positive patients.
Purpose of the Study:
- To review and analyze published cases of HIV-associated ALCL.
- To describe the clinical presentation, characteristics, and survival of this patient group.
- To identify prognostic factors in HIV-associated ALCL.
Main Methods:
- Systematic review of published literature.
- Identification and analysis of 37 cases of HIV-associated ALCL.
- Statistical analysis of patient demographics, clinical features, and outcomes.
Main Results:
- HIV-associated ALCL occurred in younger males (median age 38, 4:1 M:F ratio) with low CD4 counts (median 83 cells/mm(3)).
- Anaplastic lymphoma kinase expression was rare; Epstein-Barr virus was associated in one-third of cases.
- Lymphomas predominantly showed extranodal involvement, aggressive clinical course, and a median overall survival of 5 months.
Conclusions:
- HIV-associated ALCL is an aggressive extranodal lymphoma with poor prognosis.
- Chemotherapy and early stage at presentation are favorable prognostic indicators.
- Highly active antiretroviral therapy (HAART) may improve survival in HIV-associated ALCL.
